A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated for activity against Trypanosoma brucei brucei. Four compounds have been found to possess significant activity, in the nanomolar range, and represent hits for further optimisation towards novel treatments for Human and Animal African Trypanosomiases. Moreover, SAR indicates that the head group linking moiety is a significant modulator of biological activity
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatm...
: A library of novel pyridylchalcones were synthesised and screened against Trypanosoma brucei rhode...
A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated...
AbstractA series of 32 structurally diverse MGBs, derived from the natural product distamycin, was e...
Animal African trypanosomiasis (or nagana) is a wasting livestock disease found in sub-Saharan Afric...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated...
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (H...
Current treatments for African trypanosomiasis are either toxic, costly, difficult to administer, or...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
Human African Trypanosomiasis is a neglected parasitic disease caused by Trypanosoma brucei, which i...
AbstractA number of hydroxamic acid derivatives which inhibit human histone deacetylases were invest...
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), c...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatm...
: A library of novel pyridylchalcones were synthesised and screened against Trypanosoma brucei rhode...
A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated...
AbstractA series of 32 structurally diverse MGBs, derived from the natural product distamycin, was e...
Animal African trypanosomiasis (or nagana) is a wasting livestock disease found in sub-Saharan Afric...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated...
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (H...
Current treatments for African trypanosomiasis are either toxic, costly, difficult to administer, or...
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa be...
Human African Trypanosomiasis is a neglected parasitic disease caused by Trypanosoma brucei, which i...
AbstractA number of hydroxamic acid derivatives which inhibit human histone deacetylases were invest...
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), c...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatm...
: A library of novel pyridylchalcones were synthesised and screened against Trypanosoma brucei rhode...